(Updated - April 27, 2026 12:19 PM EDT)

Barclays analyst Etzer Darout raised the price target on Oruka Therapeutics ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Oruka Therapeutics (ORKA) PT Raised to $200 at GuggenheimApril 27, 2026 11:24 AM Oruka Therapeutics (ORKA) PT Raised to $165 at WedbushApril 27, 2026 10:10 AM Oruka Therapeutics (ORKA) PT Raised to $151 at BTIGApril 27, 2026 10:06 AM Oruka Therapeutics (ORKA) PT Raised to $150 at StifelApril 27, 2026 9:36 AM Form 8-K Oruka Therapeutics, Inc. For: Apr 27April 27, 2026 8:01 AM Oruka Therapeutics (ORKA) PT Raised to $133 at JefferiesApril 27, 2026 7:54 AM Stifel on Oruka Therapeutics (ORKA): 'We expect shares to trade meaningfully-higher'April 27, 2026 7:17 AM Oruka Therapeutics reports positive psoriasis trial data for ORKA-001April 27, 2026 7:00 AM Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque PsoriasisApril 27, 2026 7:00 AM Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026April 26, 2026 12:00 PM